GK

Glycerol kinase · P32189 · GK on Sugi Atlas →

655 patent compounds predicted against GK, 602 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Diadenosine Tetraphosphate (SCHEMBL849869)	0.81	1/20
SCHEMBL1744586	0.81	1/20
SCHEMBL2934890	0.81	1/20
Diadenosine Tetraphosphate (SCHEMBL4069414)	0.81	1/20
SCHEMBL4357990	0.81	1/20
Diadenosine Tetraphosphate (SCHEMBL4363130)	0.81	1/20
SCHEMBL6516963	0.81	1/20
Diadenosine Tetraphosphate (SCHEMBL10069136)	0.81	1/20
Diadenosine Tetraphosphate (SCHEMBL14205963)	0.81	1/20
SCHEMBL21067711	0.81	1/20
Diadenosine Tetraphosphate (SCHEMBL29359745)	0.81	1/20
SCHEMBL29366123	0.81	1/20
SCHEMBL29385225	0.81	1/20
SCHEMBL29468896	0.81	1/20
SCHEMBL29602324	0.81	1/20
SCHEMBL29810835	0.81	1/20
SCHEMBL30583138	0.81	1/20
Diadenosine Tetraphosphate (SCHEMBL31079560)	0.81	1/20
SCHEMBL13614624	0.81	1/20
SCHEMBL14017403	0.81	1/20

Clinical trials — most relevant to GK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging	PHASE4	COMPLETED
Genomic Outcomes of Metformin	PHASE4	COMPLETED
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon	PHASE4	COMPLETED
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity	PHASE2/PHASE3	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
A Multi-center 12-week Study of HMS5552 in T2DM	PHASE2	COMPLETED
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA	PHASE1	COMPLETED
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia	PHASE1	RECRUITING
Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)	PHASE1	COMPLETED
A Longitudinal Study on Short-term Effects of Gastric Bypass on Glucose Homeostasis in Obesity	nan	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Effects of Dietary Proteins on Hepatic Lipid Metabolism	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Insulin Resistance in Relation to Hyperthyroidism and Hypothyroidism	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Acute Effect of Fructose on Lipid Metabolism and Gender Differences	nan	COMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
McArdle Disease Treatment by Ketogenic Diet	nan	COMPLETED
Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes	nan	COMPLETED
Extracellular Vesicles, Insulin Action, and Exercise	nan	RECRUITING
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)	nan	WITHDRAWN
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Tissue Lipids and Insulin Resistance	nan	WITHDRAWN
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GK binder may also engage these)

Protein	Name	Similarity
Q64516	—	1.000	Q64516 →
Q0IID9	—	1.000	Q0IID9 →
Q63060	—	1.000	Q63060 →
Q14409	—	1.000	Q14409 →
Q14410	—	0.961	Q14410 →
Q9WU65	—	0.954	Q9WU65 →
Q4R4D5	—	0.953	Q4R4D5 →
Q9CQ65	—	0.941	Q9CQ65 →
Q86V21	—	0.937	Q86V21 →
Q3MHF7	—	0.934	Q3MHF7 →
Q9N0E1	—	0.932	Q9N0E1 →
Q5ZLG0	—	0.930	Q5ZLG0 →
F6V515	—	0.930	F6V515 →
E2R222	—	0.929	E2R222 →
Q5XHZ9	—	0.928	Q5XHZ9 →
Q9H3S4	—	0.927	Q9H3S4 →
TRIP13	Pachytene checkpoint protein 2 homolog	0.927	landscape →
Q5ZIH0	—	0.925	Q5ZIH0 →
Q9H9T3	—	0.924	Q9H9T3 →
D3K5L7	—	0.924	D3K5L7 →
Q9D2R0	—	0.923	Q9D2R0 →
P63143	—	0.922	P63143 →
Q9JMI1	—	0.922	Q9JMI1 →
Q4PJK1	—	0.921	Q4PJK1 →
Q3UA06	—	0.921	Q3UA06 →
Q5HZM6	—	0.920	Q5HZM6 →
A4IHW6	—	0.920	A4IHW6 →
Q17QL1	—	0.920	Q17QL1 →
Q9PWR1	—	0.920	Q9PWR1 →
Q9CWS4	—	0.920	Q9CWS4 →